Moscarella Elisabetta, Ielasi Alfonso, De Angelis Maria Carmen, di Uccio Fortunato Scotto, Cerrato Enrico, De Rosa Roberta, Campo Gianluca, Varricchio Attilio
Laboratory of Invasive Cardiology, Santa Maria della Pietà Hospital, Nola, Napoli, Italy.
Division of Cardiology, ASST Bergamo Est, "Bolognini" Hospital, Seriate (BG), Italy.
J Thorac Dis. 2017 Aug;9(Suppl 9):S969-S978. doi: 10.21037/jtd.2017.06.136.
Bioresorbable vascular scaffolds (BRS) represent the latest innovation in the field of interventional cardiology. BRS have recently been introduced in routine clinical practice and their use has progressively extended in everyday clinical practice. The BRS use appears theoretically attractive in patients presenting with acute coronary syndromes (ACS) as they are generally young with long life expectancy, thus possibly benefiting more of the so-called vascular reparative therapy. Furthermore, "culprit" lesions are usually softer and more easily expandable by current BRS compared to stable chronic lesions. However an increased risk of BRS thrombosis has been reported in clinical trials excluding ACS patients. Therefore, concerns have been raised on the safety of BRS implantation in the ACS setting in which the risk of thrombotic recurrences is definitely higher (compared to stable lesions) independently by the device implanted. Aim of this review is to provide an overview of the available data on the BRS performance in ACS patients.
生物可吸收血管支架（BRS）是介入心脏病学领域的最新创新成果。BRS最近已被引入常规临床实践，并且其应用在日常临床实践中逐渐得到扩展。BRS的应用在急性冠状动脉综合征（ACS）患者中理论上似乎很有吸引力，因为这些患者通常较为年轻，预期寿命较长，因此可能从所谓的血管修复治疗中获益更多。此外，与稳定的慢性病变相比，当前的BRS通常更容易使“罪犯”病变变软并扩张。然而，在排除ACS患者的临床试验中，已报告BRS血栓形成风险增加。因此，对于在ACS环境中植入BRS的安全性存在担忧，在这种环境中，无论植入何种装置，血栓复发的风险肯定更高（与稳定病变相比）。本综述的目的是概述ACS患者中BRS性能的现有数据。
